Introduction
Cisplatina nd its derivatives have been established as significant chemotherapeutic drugs used in the clinic for av ariety of cancers. [1] [2] [3] [4] Cisplatin is commonly used in ovarian and lung cancers,m ostly in combination with other drugs. [5] [6] [7] [8] [9] [10] [11] Oxaliplatin, ad erivative of cisplatin, is often used in colon cancer,especially in combination with fluorouracil. [12] [13] [14] However, development of resistance to thesed rugs and the toxicityo ft he Pt ion led to as earch for other metal-based drugs. Amongt he transition metalstested, two titanium-based complexes-budotitane and titanocene dichloride-reached clinical trials, but failed due to rapid hydrolysis and the formation of undefineda ggregates. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] To overcome these obstacles, our laboratory developed an ew family of titanium(IV) complexes based on phenolato ligands. [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] In particular,d iaminobis(phenolato)-bis(alkoxo)Ti IV (phenolaTi,F igure 1) demonstrated remarkable stability in aqueous media and an extended shelf life, along with enhanced in vitro cytotoxicity toward various cancer cell types. [43] In previous studies, the phenolaTic omplex also displayeds ynergistic or additive characteristics when combined in vitro with cisplatin or oxaliplatin, [44] and an antitumorigenic effect when tested in vivoi nm ice inoculated with lymphoma growinga s ascites. [43] Furthermore, evaluating this complex on the NCI-60 panel of human cancer cell lines (by the Developmental Therapeutics Program( DTP) of the US National Cancer Institute (NCI)), demonstrated significant cytotoxicity (with an average GI 50 value of 4.7 AE 2 mm)t oward all cell lines tested, particularly colon and lung. Of added significance wereo ur findings that phenolaTi is also active in vitro against cisplatin-resistant, as well as MDR1 (ABCB1) drug-resistantcells, suggesting adistinct mechanism of action. [43] Here, we expando ur findings to include the in vivo effect of phenolaTio nd ifferents olid tumors, Due to the toxicityo fp latinum compounds used in the clinic as anticancer chemotherapies, titanium serves as as afe and attractive alternative. Lately,w ei ntroduced an ew family of Ti complexes based on readily available phenolato ligands, demonstratingi ncredibly high hydrolytic stability, with the lead compound phenolaTid emonstrating wide cytotoxic activity toward the NCI-60 panel of human cancer cell lines, with an average GI 50 value of 4.7 AE 2 mm.H erein, we evaluated in vivo: a) the safety,a nd b) the growth inhibitory capacity (efficacy) of this compound. PhenolaTiw as found to be effective in vivo againstc olon (CT-26) andl ung (LLC-1) murine cell lines in syngeneic hosts and toward ah uman colon cancer (HT-29) cell line in immune-deficient (Nude)m ice, with an efficacy similar to that of known chemotherapy.N otably,n oc linical signs of toxicityw ere observed in the treated mice, namely,n oe ffect on body weight, spleen weight or kidney function, unlike the effects observed with the positive control Pt drugs.S tudies of combinationso fp henolaTi and Pt drugs provided evidence that similare fficacy with decreased toxicitym ay be achieved, which is highly valuable for medicinal applications.
[a] N. Ganot of both murine and human origin, and comparethese findings, in terms of toxicitya nd efficacy,w ith those of the two commonly used platinum-based drugs relevant to the tested cancer types:c isplatin and oxaliplatin. In particular,c ombination studies enabled the achievement of high efficacy with reduced toxicity.
Results

In vitro cytotoxicity
In vitro cytotoxicity of phenolaTiw as tested previously toward severalc ell lines, including human HT-29 colon cancer cells. [43, 44] In an effort to increase solubility of the complex in aqueous media, nanoparticles of phenolaTic omplex were obtained as previously described by ar apid conversion of av olatile oil-in-water microemulsion into adry powder,c omposed of nanoparticles. [36] The in vitro effect of this emulsion on murine colon CT-26 and lung LLC-1 cancer cell lines is demonstrated in Figure 2 . Previous studies also gave evidence that the nanoparticlef ormulation does not significantly impact the cytotoxicity and is itselfinactive. [36, 38] In vivo toxicity Balb/c mice were subjected to PBS (control), phenolaTi (1.6 mg kg
À1
,t he highest concentration soluble without formulation), cisplatin (5 mg kg À1 ), or oxaliplatin (5 mg kg À1 )e very other day for four weeks. Whereas mice treated with cisplatin or oxaliplatin demonstrated av ariety of deleterious effects, including decreased body weight andg rooming, culminating in diminished survival (Figure 3 ), mice treated with phenolaTis urvived the chemotherapeutic challenge, and did not demonstrate any of these symptoms. Notably,a lthough increasing the phenolaTic oncentrationt o4 0mgkg À1 in formulation still did not bring about any signs of toxicity in the treated mice (after five injections;t reatment frequency:e very other day), increasingi tf urther to 80 mg kg À1 caused sudden mortality after the third injection (treatment frequency:e very other day).
As cisplatin induces nephrotoxicity,w es oughtt ot est whether phenolaTih as as imilar effect on the kidney.I nterestingly,7 2h following the injection of the drugs (20 mg kg À1 , i.p.) marked increases in urine excretion-to-water consumption ratio ( Figure 4A ), BUN levels ( Figure 4B ), urinary albumin-to- . Note that only cisplatin resultedi ni ncreased urine excretionto-water consumption ratio (A), blood urea nitrogen (BUN;B), albumin-tocreatinineration( ACR;C), urine albumin levels (D), and urinary kidney injury marker1(KIM-1;E)a sw ell as reducedc reatinineclearance (F). Data are the mean AE SEM in 4-5 animals per group. *P < 0.05 relative to vehicle-treated group; # P < 0.05 relative to cisplatin-treated group. creatinine ratio (ACR;F igure 4C), albuminuria ( Figure 4D ), and KIM-1 levels ( Figure 4E )w ere observed in C57BL/6 mice treated with cisplatin, comparedw ith vehicle-treated control animals. In addition, as ignificant reduction in CCr ( Figure 4F )w as also documentedi nc isplatin-treated mice. None of these changes were found in phenolaTi-treated mice. Ta ken together, these findings suggestt hat phenolaTii sp ractically nontoxic in mice when compared with both cisplatin and oxaliplatin, which encouraged further efficacy studies.
In vivo efficacy
As eries of tumor growth inhibition studies by phenolaTiw ere carried out. PhenolaTiw as first tested in comparison with cisplatin on Balb/c and C57BL/6 mice inoculated s.c. with CT-26 and LLC-1 cells, respectively ( Figure 5 ). PhenolaTi( 0.5-5mgkg
À1
)w as employed both directly and in nanoparticles form marked as "phenolaTiF"t oi ncrease solubility and enable higher doses, whereby the dose mentioned is the dose of the active agent in the formulated compound. Generally,treatment started immediatelyf ollowing detection of tumors, and grouping the animals uniformly.W hereas both drugs demonstrated as imilar in vivo efficacy on both models, phenolaTid emonstrated no decrease in body weight relative to cisplatin. Interestingly, the presence of the formulation only slightly impacted the efficacy,w hereby increasing the dose of actived rug in formulationd id not increase the efficacy of phenolaTi. Additionally,i na nothere xperiment using phenolaTi, phenolaTiF ,a nd cisplatin on Nude mice inoculated with cisplatin-resistant A2780-CP human ovarian cancer cells, am arkedly decreased efficacy was observed for the cisplatin-treated relativet ot he phenolato-treated groups ( Figure S1 , Supporting Information).
In an additional set of experiments,u sing the above-mentioned mice strainsa nd cancer cell lines,t he effect of ac ombination of phenolaTia nd cisplatin was addressed. PhenolaTi and cisplatin werec omparedw ith regards to tumorg rowth inhibition( tumor volume and weight) as well as toxicity (body and spleen weight) ( Figure 6 ). In both models, the combinations showede nhanced efficacy.N otably,t he spleen weights of mice treated with cisplatin were lower than those of the controlg roup, whereas the spleenso ft hose treatedw ith phenolaTia nd phenolaTiFremained similart ot hose of the control group. Furthermore, within the timeframes used (up to 17 and 15 days post-inoculation for Figures6A, B, respectively), phenolaTid id not enhancet he toxic outcomes of cisplatin treatment, while again demonstrating antitumorefficacy.
The studies were expanded to include ah uman cancer model.F indings similart ot he above were observed with immune-deficientN ude mice, inoculated s.c. with human HT-29 colon adenocarcinoma cells that were subjected to phenolaTi, phenolaTi F, cisplatin, and oxaliplatin commonly used in the clinicf or colon cancer. Mice were subjected to i.p. injections of the drugs every day/other day.A ll drugs (or combinations thereof)w ere antitumorigenic with the combinationo f phenolaTi with cisplatin showing increased efficacy.I no ne experiment ( Figure 7A ), the side effects of cisplatin were even somewhat diminished when combined with phenolaTi,w hereby the body weights remained similart ot hat in the control group. Thus, the phenolaTic onsistently showed no side effects relative to the marked toxicity demonstrated by cisplatin alone, although decreased effects were developed by oxaliplatin as well. Nevertheless, somewhat reduced efficacy waso bserved for oxaliplatin and its combinations.
Nephrotoxicity test
The Nude mice inoculated with HT-29 cells and treated with phenolaTi or cisplatin ( Figure 7B )u nderwent evaluation for chronicr enal dysfunction by morphological damage to the kidney. Histological examination revealed necrosis, protein casts, vacuolization and desquamationo fr enal tubulare pithelial cells in the cisplatin-treated mice. PhenolaTi at 5mgkg À1 did not cause tubulard amage as determined by PAS stainingo ft he kidney (Figure 8 ), indicating no nephrotoxicity induced by the novel drug.
Discussion
This is the first study to demonstrate that both phenolaTia nd its formulatedv ersion phenolaTiF effectively impair solid tumord evelopment in both immune-competent and immune-deficientm ice injected with murinea nd human cancer cell lines, respectively,i ncluding cisplatin-resistant ovarian carcinoma cells. Of added significance is the lack of apparentt oxicity that distinguishes the Ti drug from the commonly used Pt-basedc hemotherapeutics. No body weightl oss or spleen weight changes were de- tected in phenolaTi-treated animals, as well as no hair loss, grooming or any behavioral changes.M oreover,b ecause cisplatin is known to be nephrotoxic,v arious parameters relating to kidney function were evaluated and none were impaired by the phenolaTicomplex. Therefore, the phenolaTit itanium complex is an attractive candidatefor anticancer chemotherapy.
Combinationtherapy is ac ommon methodology,a sc ombining drugs may achieve ad esired effect with reduced doses of each drug, therebyr educing side effects. In addition, multiple mechanisms of action can overcomed rug resistance. [45] [46] [47] [48] In all combinations studied herein, no antagonistic behaviors were detected, implying unrelated mechanisms, as also supported by previous NCI-60 results. [43] Moreover,i ns ome experiments the combined drugs achieved better efficacy than each drug alone, whereas the side effects of cisplatin remained similar as when the drug was administered alone;t herefore, combining phenolaTiw ith ad ecreasedc oncentration of cisplatin gave similare fficacy,but with reduced Pt-generated side effects.
In the presents tudy,i no rdert of ind an optimal dose for treatment, especiallyc onsidering the lack of toxicityo fp henolaTi, various concentrations of phenolaTiw eree xamined. Interestingly,aclear dose-response was not detected, which may imply that alternative formulationss hould be evaluated. As the formulationd egradation in the animal is presently unknown,i ti sp ossible that the active material is released before arrivinga ti ts biological target, and due to the limited solubility,i so nly partially effective. Because the efficacy of phenolaTii na ll concentrations used was high (mostly TGI > 50 %), and also similar to that of cisplatin, it is also possible that the efficacy recorded is the highest achievable under the experimental conditions.
Conclusions
The phenolaTic omplex is an effectivea nticancer drug as established on several murine and human solid tumor modelsa nd is nontoxic at ar ange of highly effective doses. Ta ken together with the ability to circumvent drug resistance, this complexi sa na ttractive novel anticancer drug. Further preclinical studies with alternative formulations shoulds pecifically establish the therapeutic window and pharmacokinetics of the drug, to enable its subsequente valuation in clinical settings.
Experimental Section
Drugs and chemicals:P henolaTiw as synthesized as previously described. [43] Cis-dichlorodiammine platinum(II) (cisplatin) 99 %w as purchased from Acros (cat. 193760010), and oxaliplatin was purchased from Glentham Life Scientific Ltd. (cat. GP0792). Nanoparticles powder was prepared as previously described, increasing solubility of phenolaTii nw ater from 0.4 to 25 mg mL À1 . [36, 43] Cells:H T-29 (HTB-38TM) human colon cancer cells, as well as CT-26 (CRL-2638TM) and LLC-1 (CRL-1642TM) murine colon and lung cancer cells, respectively,w ere obtained from ATCC Inc. (VA, USA). HT-29 and CT-26 cells were maintained as attached culture in a medium containing:1%p enicillin/streptomycin antibiotics, 1% lglutamine, 10 %f etal bovine serum (FBS), and 88 %R PMI-1640 medium, (all purchased from Biological Industries Inc.,B et- Haemek, Israel) in ah umidified atmosphere of 5% CO 2 at 37 8C. LLC-1 cells were maintained under similar conditions but with DMEM instead of RPMI-1640.
Mice:B alb/c, C57BL/6, and immune-deficient (Nude) female mice (5-6 weeks old) were obtained from Harlan (Israel) and held in an SPF facility (AAALAC accreditation #1285). Mice were treated in accordance with NIH guidelines and approval by the institutional committee for ethics in animal experimentation.
Growth inhibition assay:C ytotoxicity was measured on CT-26 colon cells and LLC-1 lung cells using the MTT assay as previously described. [49] Approximately 0.6 10 6 cells in medium were seeded into a9 6-well plate and allowed to attach for ad ay.T he cells were consequently treated with the reagent tested at 10 different concentrations. Doses for control Pt-based drugs were selected based on literature and toxicity limitations. [50] [51] [52] [53] After as tandard of 3days incubation, MTT (0.1 mg in 20 mLR PMI) was added and the cells were incubated for additional 3h.A fter the incubation period, the MTT solution was removed, and the cells were dissolved in 200 mLi sopropanol. The absorbance at 550 nm was measured by aS park 10M Multimode Microplate Reader spectrophotometer (Tecan Group Ltd. Mannedorf, Switzerland). Relative IC 50 values were determined by a nonlinear regression of avariable slope (four parameters) model by GraphPad Prism 5.04 software, with error values based on the STD of at least 3 3r epetitions (three separate measurements conducted on three different days to give nine repeats altogether). Cytotoxicity measurements on HT-29 human colon cancer cells were published previously. [44] In vivo studies:F or tumor growth inhibition experiments, 5-6-week-old Balb/c mice, C57BL/6, or immunedeficient (Nude) mice were inoculated subcutaneously (s.c.) with 1 10 6 CT-26 colon cancer cells, 5 10 5 LLC-1 lung cancer cells, or 5 10 6 HT-29 human colon adenocarcinoma cells, respectively.T umors manifested within 4-10 days post-inoculation when mice were randomized into groups with similar average tumor dimensions. The mice were then treated 3t o5times weekly with the tested drug by intraperitoneal (i.p.) injections. Control groups were subjected to phosphate-buffered saline (PBS) or microemulsion solution in PBS devoid of the active drug. For all models, tumor volume (length width 2 0.52) was assessed by caliper measurements every 2t o4 days. Mice were euthanized once the tumors reached ethical limit of 15 mm length or if the animals displayed health indicators that met the ethical criteria for sacrifice. Tumor growth inhibition (TGI) was defined as the difference in size between mean control group and mean treated group, expressed as ap ercentage of mean control group:% TGI = [1À(mean drug-treated / mean control )] 100. Ar egimen of an agent that produces at least 50 %T GI is generally classified as potentially therapeutically active.
Histological examination for tubular damage:F ollowing euthanasia, kidneys were removed and fixed with 10 %f ormalin, renal tissues were sectioned (3 mm) and stained with periodic acid-Schiff (PAS) reagents for histological examination. Tubular damage in PAS-stained sections was examined by microscopy (200 magnification) as described earlier. [54] Nephrotoxicity test:E ight-to 10-week-old male C57BL/6 mice were euthanized 72 ha fter as ingle i.p. injection (20 mg kg
À1
)o f cis-diammineplatinum(II) dichloride (cisplatin), phenolaTi, or PBS as av ehicle control. Urine was collected before euthanasia using mouse metabolic cages (CCS2000 Chiller System, Hatteras Instruments, NC, USA). Blood was collected under deep anesthesia by retro-orbital bleeding, and serum and urine levels of creatinine as well as serum urea levels were measured using the Cobas C-111 chemistry analyzer (Roche, Switzerland). Blood urea nitrogen (BUN) was calculated by serum urea levels (BUN mg dL À1 = [urea] mm 2.801). Creatinine clearance (CCr) was calculated using urine and serum creatinine levels (CCr mL h À1 = [urine creatinine] mg dL À1 (urine volume)/[serum creatinine] mg dL À1 24 h). Urine levels of al- and body weight (right). For combinations:the added drugs wereapplied at the same concentration each as whenapplied alone;"1/2 cisplatin" or "1/2 oxaliplatin" refers to half the concentrationoft he Pt drug as applied alone. Data are the mean AE SEM in 5-10 animals per group. *P < 0.0001 relative to control;**P < 0.01 relativetocontrol; # P < 0.0001r elative to cisplatin-treatedgroup. (Table S1 ).
